Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha. Amarillo Biosciences.

Dale L Barnard1

  • 1Utah State University, Institute for Antiviral Research, Logan 84322-5600, USA. honery@cc.usu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining the interactions of Galahad™ compound with viruses to develop a novel inactivated influenza A virus vaccine.

Heliyon·2022
Same author

Coronaviruses: Molecular and Cellular Biology.

Future virology·2020
Same author

Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.

Scientific reports·2019
Same author

Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro.

Antiviral research·2018
Same author

Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.

ACS infectious diseases·2017
Same author

Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol<sup>®</sup> (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model.

Antiviral research·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Amarillo Biosciences is developing low-dose oral interferon-alpha (IFNalpha) for various conditions, including Sjøgren

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Interferon-alpha (IFNalpha) is being investigated for its therapeutic potential.
  • Low-dose oral formulations offer a novel delivery method.

Purpose of the Study:

  • To explore the efficacy of low-dose oral interferon-alpha (IFNalpha) as a treatment.
  • To evaluate topical IFNalpha for specific indications.

Main Methods:

  • Development of low-dose oral IFNalpha (Veldona).
  • Development of a topical IFNalpha formulation.
  • Licensing agreements for specific indications.

Main Results:

  • Oral IFNalpha is being developed for Sjøgren's syndrome, oral mucositis, HBV, HCV, and bone marrow disorders.

Related Experiment Videos

  • Topical IFNalpha is under development for genital warts.
  • Oral IFNalpha is registered in Ghana for HBV infection.

    • Conclusions:

    • Low-dose oral IFNalpha shows promise across multiple therapeutic areas.
    • Further development is ongoing for various indications, including orphan diseases.